SCHEMBL23054844

SCHEMBL23054844

N#Cc1ccc(NC(=O)CCCCCCC(=O)O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.58
ALDH1A1 P00352 1/20 0.58
HDAC4 P56524 8/20 0.54
HDAC1 Q13547 8/20 0.54
HDAC7 Q8WUI4 8/20 0.54
HDAC11 Q96DB2 8/20 0.54
HDAC8 Q9BY41 8/20 0.54
HDAC6 Q9UBN7 8/20 0.54
HDAC9 Q9UKV0 8/20 0.54
HDAC5 Q9UQL6 8/20 0.54
HDAC3 O15379 7/20 0.54
HDAC2 Q92769 7/20 0.54
HDAC10 Q969S8 7/20 0.54
RORC P51449 2/20 0.53
MEN1 O00255 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52
KDM4E B2RXH2 1/20 0.51
BRD4 O60885 1/20 0.51
NCOR1 O75376 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15899425 0.98 POLB (0.59) POLBALDH1A1HDAC4HDAC1HDAC7
SCHEMBL9223532 0.95 POLB (0.64) POLBALDH1A1RORCMEN1MAPT
SCHEMBL3084650 0.89 RORC (0.59) POLBALDH1A1RORCMEN1MAPT
SCHEMBL15480399 0.88 HDAC1 (0.65) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL15480393 0.86 PGR (0.65) POLBRORCGAAL3MBTL1PGR
SCHEMBL20777973 0.86 PGR (0.65) POLBRORCGAAL3MBTL1PGR
SCHEMBL8638627 0.86 RORC (0.52) POLBHDAC4HDAC1HDAC7HDAC11
SCHEMBL13716356 0.84 RORC (0.53) POLBHDAC4HDAC1HDAC7HDAC11
SCHEMBL7473435 0.83 POLB (0.53) POLBALDH1A1HDAC4HDAC1HDAC7
SCHEMBL23054775 0.82 LMNA (0.63) ALDH1A1HDAC4HDAC1HDAC7HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 POLB 2496/4885ALDH1A1 3068/4885HDAC4 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.